ValuEngine cut shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a hold rating in a research note issued to investors on Thursday morning.
TBPH has been the topic of several other reports. Needham & Company LLC reissued a buy rating and issued a $40.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, August 1st. BidaskClub raised shares of Theravance Biopharma from a hold rating to a buy rating in a research note on Friday, September 28th. Piper Jaffray Companies reissued a buy rating on shares of Theravance Biopharma in a research note on Tuesday, October 23rd. Finally, Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the company a buy rating in a research note on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Theravance Biopharma currently has an average rating of Hold and an average target price of $45.25.
Shares of Theravance Biopharma stock traded up $0.37 during trading on Thursday, reaching $25.22. The company’s stock had a trading volume of 3,859 shares, compared to its average volume of 227,592. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -4.63 and a beta of 1.88. Theravance Biopharma has a fifty-two week low of $21.27 and a fifty-two week high of $35.48. The company has a debt-to-equity ratio of 6.52, a current ratio of 4.14 and a quick ratio of 3.95.
Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.44. The business had revenue of $23.48 million for the quarter, compared to analysts’ expectations of $9.97 million. Theravance Biopharma had a negative net margin of 640.07% and a negative return on equity of 261.70%. Analysts anticipate that Theravance Biopharma will post -4.41 earnings per share for the current year.
In other news, CFO Renee D. Gala sold 43,743 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $26.79, for a total transaction of $1,171,874.97. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Bradford J. Shafer sold 31,300 shares of the company’s stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $27.94, for a total transaction of $874,522.00. Following the transaction, the executive vice president now directly owns 127,606 shares in the company, valued at $3,565,311.64. The disclosure for this sale can be found here. Insiders sold a total of 88,555 shares of company stock worth $2,425,865 over the last three months. 6.10% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the company. UBS Group AG grew its stake in shares of Theravance Biopharma by 88.4% during the 1st quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 2,117 shares during the period. Xact Kapitalforvaltning AB acquired a new position in shares of Theravance Biopharma during the 1st quarter worth $202,000. Royal Bank of Canada grew its stake in shares of Theravance Biopharma by 22.3% during the 1st quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 3,042 shares during the period. State Board of Administration of Florida Retirement System grew its stake in shares of Theravance Biopharma by 12.2% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 28,578 shares of the biopharmaceutical company’s stock worth $648,000 after purchasing an additional 3,100 shares during the period. Finally, Engineers Gate Manager LP acquired a new position in shares of Theravance Biopharma during the 3rd quarter worth $662,000. 84.70% of the stock is currently owned by institutional investors and hedge funds.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
Featured Story: Diversification Important in Investing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.